Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma.
Journal of Clinical Oncology.
Times cited: 58
Pembrolizumab for the treatment of non-small-cell lung cancer.
New England Journal of Medicine.
Times cited: 1437